Caribou Biosciences (CRBU) Projected to Post Quarterly Earnings on Tuesday

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.42) per share for the quarter.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its quarterly earnings results on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.01. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The business had revenue of $2.08 million during the quarter, compared to analysts' expectations of $2.11 million. On average, analysts expect Caribou Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Caribou Biosciences Stock Performance

Shares of CRBU stock traded up $0.08 on Friday, hitting $0.88. The company's stock had a trading volume of 1,023,212 shares, compared to its average volume of 1,556,668. The company has a market capitalization of $81.84 million, a PE ratio of -0.53 and a beta of 2.36. The stock's 50 day moving average is $0.93 and its 200-day moving average is $1.51. Caribou Biosciences has a fifty-two week low of $0.66 and a fifty-two week high of $3.93.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on CRBU shares. Bank of America decreased their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. HC Wainwright reaffirmed a "buy" rating and set a $3.00 price objective (down previously from $9.00) on shares of Caribou Biosciences in a research report on Monday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Caribou Biosciences currently has a consensus rating of "Buy" and a consensus price target of $9.33.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.